Clinical trialNCT07886905Not, yet, recruitingPhase 2Interventional

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

SponsorWashington University School of MedicineEnrollment12Anaplastic Thyroid CarcinomaThyroid CancerThyroid Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a single institution non-randomized phase 2 trial looking at the effect of Pulsed Stereotactic Ablative Radiotherapy (PULSAR) followed by neoadjuvant chemotherapy dabrafenib and trametinib (DT) with or without pembrolizumab on patients with advanced anaplastic thyroid carcinoma (ATC). Pembrolizumab will be administered per standard of care (SOC) only to patients who are PDL1 positive at screening.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Nikhil Rammohan, MD, PhD
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Washington University School of Medicine
St Louis, Missouri, United States
Anthony Apicelli, MD, PhDBenjamin Wahle, MDBrendan Knapp, MDChristine Auberle, MDDouglas Adkins, MDEric Laugeman, MSEsther Lu, PhDJason Rich, MDJennifer De Los Santos, MDJesse Zaretsky, MD, PhDJoseph Harms, PhDNikhil Rammohan, MD, PhDPatrik Pipkorn, MDPaul Zolkind, MDPeter Oppelt, MDR Alex Harbison, MDRyan Jackson, MDSana Karam, MD, PhDSidharth Puram, MD, PhDStephanie Markovina, MD, PhDWade Thorstad, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dabrafenib →Pembrolizumab →Trametinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2026
Primary completion: 8 Apr 2029
Completion: 13 May 2029
Last update posted: 21 Oct 2026
Registered enrollment: 12
Registry id: NCT07886905

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.